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Abstract
The Greig cephalopolysyndactyly syndrome (GCPS) is a pleiotropic, multiple congenital anomaly
syndrome. It is rare, but precise estimates of incidence are difficult to determine, as ascertainment is
erratic (estimated range 1–9/1,000,000). The primary findings include hypertelorism, macrocephaly with
frontal bossing, and polysyndactyly. The polydactyly is most commonly preaxial of the feet and postaxial
in the hands, with variable cutaneous syndactyly, but the limb findings vary significantly. Other low
frequency findings include central nervous system (CNS) anomalies, hernias, and cognitive impairment.
GCPS is caused by loss of function mutations in the GLI3 transcription factor gene and is inherited in an
autosomal dominant pattern. The disorder is allelic to the Pallister-Hall syndrome and one form of the
acrocallosal syndrome.
Clinical diagnosis is challenging because the findings of GCPS are relatively non-specific, and no specific and
sensitive clinical have been delineated. For this reason, we have proposed a combined clinical-molecular
definition for the syndrome. A presumptive diagnosis of GCPS can be made if the patient has the classic
triad of preaxial polydactyly with cutaneous syndactyly of at least one limb, hypertelorism, and
macrocephaly. Patients with a phenotype consistent with GCPS (but which may not manifest all three
attributes listed above) and a GLI3 mutation may be diagnosed definitively with GCPS. In addition, persons
with a GCPS-consistent phenotype who are related to a definitively diagnosed family member in a pattern
consistent with autosomal dominant inheritance may be diagnosed definitively as well. Antenatal molecular
diagnosis is technically straightforward to perform.
Differential diagnoses include preaxial polydactyly type 4, the GCPS contiguous gene syndrome,
acrocallosal syndrome, Gorlin syndrome, Carpenter syndrome, and Teebi syndrome.
Treatment of the disorder is symptomatic, with plastic or orthopedic surgery indicated for significant limb
malformations.
The prognosis for typically affected patients is excellent. There may be a slight increase in the incidence of
developmental delay or cognitive impairment. Patients with large deletions that include GLI3 may have a
worse prognosis.
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Greig cephalopolysyndactyly (GCPS) syndrome is named
after David Middleton Greig for his 1926 manuscript
describing a patient with this disorder [1]. Although the
name is commonly confused with that of Grieg, the Nor-
wegian composer, Greig was a Scot, whose name is pro-
nounced Gregg (with a trilled "r"). The term "Greig
syndrome" is not favored as it denotes a less specific dyad
of hypertelorism and macrocephaly [2]. The alternative
term "polysyndactyly with peculiar skull shape" is dispar-
aging and should not be used. Hootnick-Holmes syn-
drome has been suggested to be the same entity [2]. Note
that the clinical diagnostic entity of GCPS is clearly dis-
tinct from Pallister-Hall syndrome, which is allelic. GCPS
should also be distinguished from acrocallosal syndrome,
although this distinction can be difficult or impossible
without the utilization of molecular diagnostics.
Definition
The Greig cephalopolysyndactyly syndrome (GCPS) is a
rare, pleiotropic, multiple congenital anomaly syndrome
characterized by the primary clinical triad of polysyndac-
tyly, macrocephaly, and hypertelorism.
Epidemiology
The incidence of GCPS is difficult to estimate. It is impos-
sible to determine the incidence of a disorder for which
there are no reliable clinical criteria and molecular diag-
nostics are not yet in wide use. As the disorder blends in a
phenotypic continuum with non-syndromic polydactyly,
it may be much more prevalent than it seems. This author
estimates that it is in the 1–9/1,000,000 range.
Clinical description
The primary clinical triad of GCPS is polysyndactyly, mac-
rocephaly, and hypertelorism [2-4] (Figure 1). The poly-
dactyly is classically described as preaxial, and may occur
in any limb. Postaxial polydactyly may be more common
than preaxial and in our experience, the most common
finding is postaxial polydactyly of the hands and preaxial
polydactyly of the feet. The severity of the polydactyly var-
ies widely, among individuals and among limbs in the
same individual. This can vary from an apparently normal
extremity, through subtle broadening of the thumb or hal-
lux, tiny postaxial nubbins, to partially bifid digits, hypo-
plastic supernumerary digits, fully formed supernumerary
digits, and higher order polydactyly (this author has seen
a single patient with GCPS and octadactyly). The cutane-
ous syndactyly is also highly variable. Many patients have
none. Some patients have mild partial cutaneous syndac-
tyly of a few digits and this spectrum continues through to
complete cutaneous syndactyly of all digits, not unlike
that seen in patients with Apert syndrome.
The craniofacial manifestations are also highly variable.
Some patients have significant hypertelorism (increased
interpupillary distance) with or without telecanthus
(increased inner canthal distance). Some patients also
have macrocephaly, which is not typically associated with
central nervous system (CNS) anomalies (see section
below on GCPS-contiguous gene syndrome for exceptions
to this). The craniofacial findings of GCPS commonly
cause challenges in clinical diagnosis. First, mild hyperte-
lorism is generally considered an attractive trait, and it
may be missed by examiners not trained to recognize it.
A patient with Greig cephalopolysyndactyly [26]Figur  1
A patient with Greig cephalopolysyndactyly [26]. A. Facial view of the patient. Note the hypertelorism and macroceph-
aly. B. The hand of this patient shows a broad thumb, complete cutaneous syndactyly of digits 2–5 with fusion of the nails and a 
postaxial supernumerary digit. C. The foot of this patient shows a partially duplicated hallux with cutaneous syndactyly of sev-
eral digits.Page 2 of 6
(page number not for citation purposes)
Orphanet Journal of Rare Diseases 2008, 3:10 http://www.ojrd.com/content/3/1/10Second, because familial macrocephaly is common, this
too may be missed by inexperienced examiners. Finally,
all of these craniofacial findings are highly variable and
we have evaluated a number of multiplex GCPS families
where some affecteds had clear craniofacial findings and
some had nearly none.
Other, less common anomalies in GCPS include cranio-
synostosis, mental retardation, agenesis of the corpus cal-
losum, and umbilical and diaphragmatic hernias. In our
experience, mental retardation is not common patients
with typical GCPS. Of course, the background rate of cog-
nitive impairment in the population is 2–3%, so it is dif-
ficult to prove that a rare malformation syndrome has an
elevated or baseline risk for this complication, if only a
few hundred cases have been analyzed. We counsel fami-
lies that it is not clear at this time that GCPS has a signifi-
cantly higher rate of cognitive impairment than the
background risk. Instead, most of the risk of cognitive
impairment seems to be associated with the GCPS-contig-
uous gene syndrome (see below). Craniosynostosis was
noted in several of the earliest GCPS case reports, but we
have observed this in very few patients.
There have been several case reports of patients with GCPS
and tumors, such as leukemia and gliomas [5]. Again, it is
difficult to assign relative risks for such a putative associa-
tion, especially considering ascertainment biases.
More generally, ascertainment bias likely plays a major
role in distorting the reported frequencies of many mani-
festations of GCPS. Because patients enrolled in most clin-
ical and molecular research studies must fulfill certain
eligibility criteria, this biases case series toward more
severely affected patients. This author suspects that there
are many individuals with mild GCPS who instead carry a
diagnosis of non-syndromic polydactyly, because they
were not evaluated by a clinician familiar with the subtle-
ties of this disorder.
Etiology
More than 75% of patients with clinically recognizable
GCPS who have been evaluated in the NIH study have
been found to have mutations in GLI3 [6]. GCPS is caused
by mutations that lead to haploinsufficiency for GLI3 and,
as is typical for this mode of pathogenesis, the spectrum
of mutations is very large. We suspect that there are
patients among those who are GLI3 mutation-negative
who have cryptic mutations in this gene. However, the
gene is large (about 300 kb) and screening for all possible
null mutations is nearly impossible. It remains a possibil-
ity that some patients with a GCPS phenotype could have
mutations in genes other than GLI3, and we hypothesize
that mutations in other genes in the GLI-Sonic Hedgehog
family could cause such a phenotype.
Mutations shown to cause GCPS include nonsense, mis-
sense, and splicing mutations, and translocations, dele-
tions and insertions [6-15]. The deletions range from a
single nucleotide to nearly a megabase in size. The range
of insertions is not so broad, ranging from a single nucle-
otide to ~60 kb. A useful rule is that mutations that are
smaller than about 1 Mb generally cause typical GCPS
whereas mutations larger than this cause what we have
termed the GCPS-contiguous gene syndrome (GCPS-
CGS). This latter disorder is best considered as a distinct
clinical diagnosis. In our experience, such patients have a
high frequency of cognitive impairment and seizures. In
addition, many of these patients have a hypoplastic cor-
pus callosum and a normal or small head circumference.
We have suggested that these manifestations are non-spe-
cific and caused by the loss of numerous contiguous genes
[9].
Diagnostic criteria
It is difficult to precisely define GCPS on clinical grounds
because the major manifestations overlap substantially
with other disorders (see differential diagnosis, below).
For this reason, we have proposed a combined clinical-
molecular definition. A presumptive diagnosis of GCPS can
be made if the patient has the classic triad of preaxial poly-
dactyly with cutaneous syndactyly of at least one limb,
hypertelorism, and macrocephaly. The presumptive crite-
ria could be useful to identify patients who may benefit
from undergoing molecular analysis of GLI3. Patients
with a phenotype consistent with GCPS and a GLI3 muta-
tion may be diagnosed definitively with GCPS. In addi-
tion, persons with a GCPS-consistent phenotype who are
related to a definitively diagnosed family member in a
pattern consistent with autosomal dominant inheritance
may be diagnosed definitively as well.
Diagnostic methods
Sequencing of the GLI3 coding exons or scanning with
denaturing high performance liquid chromatography
(DHPLC), single-strand conformation polymorphism
(SSCP), or other conformation detection methods is an
appropriate first screen for patients with typical GCPS. As
noted above, the yield for mutations in patients with typ-
ical GCPS should be greater than 70%. For patients with
subclinical forms of the disorder, it may be reasonable to
use this same approach, although the yield is likely to be
lower (Biesecker et al, unpublished data).
Cytogenetic analysis should be performed either as a first
test, or in all patients who have GCPS but no mutation
was found by sequencing. This is because translocations
involving 7p have been shown to be the causative muta-
tion in a small proportion of patients with GCPS. These
mutations are important to detect because persons with
balanced translocations have a risk for offspring withPage 3 of 6
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ing a child with GCPS.
The broad range of insertions and deletions that can cause
GCPS are technically challenging to detect. No current
technology can be used to assess the full range of the dele-
tions and insertions (duplications) that have been shown
to cause this disorder. Sequencing and conformational
analysis are useful for detection of aberrations that are sig-
nificantly smaller than the polymerase chain reaction
(PCR) amplicons used in these techniques. Fluorescence
in situ hybridization (FISH), Southern blotting, loss of
heterozygosity (LOH) analysis of polymorphic markers,
quantitative PCR, and array comparative genomic hybrid-
ization (CGH) have all been used to detect duplications
and deletions, with varying success (and varying practical-
ity). FISH works well for deletions and duplications that
are about 50% or more the size of the probes used in the
assay. However, because the sizing of deletions is impor-
tant for prognosis (see above) it can be tedious to deter-
mine this with FISH. We have developed an array CGH
platform specifically designed to detect deletions and
insertions in the GLI3 region, and this platform can read-
ily assess aberrations of 10 kb and greater [16]. There is
still a need for a mutation detection platform that bridges
these technologies and it would, of course, be desirable to
have a single platform that could detect all types of aber-
rations, though none are on the horizon.
Differential diagnosis
The differential diagnosis for polydactyly is enormous,
comprising more than 100 disorders and is beyond the
scope of this chapter [17,18]. Therefore, the careful assess-
ment of sometimes subtle dysmorphic features of a
patient with polydactyly is key to making a correct diagno-
sis. The spectrum of GCPS overlaps with that of the so-
called non-syndromic preaxial polydactylies such as pre-
axial polydactyly type 4 [19]. A few disorders have sub-
stantial overlap with GCPS. The acrocallosal syndrome
comprises preaxial polysyndactyly, macrocephaly, agene-
sis of the corpus callosum, mental retardation, seizures,
and hernias [20]. It is inherited in an autosomal recessive
pattern; however, this fact is of little use in the differential
diagnosis of a simplex case. There are two further compli-
cating factors with acrocallosal syndrome. First, there is a
single case of a patient with a phenotype indistinguisha-
ble from acrocallosal syndrome who has a p.A934P GLI3
mutation [21]. Second, patients with GCPS-CGS have
substantial phenotypic overlap with acrocallosal syn-
drome [9,22]. In these situations, molecular diagnostics
are essential to arrive at a correct diagnosis. The Teebi
hypertelorism syndrome shares craniofacial manifesta-
tions with GCPS, although the polydactyly is typically not
preaxial [23]. Carpenter syndrome manifests polysyndac-
tyly and craniosynostosis, with mental retardation and
has recently been shown to be caused by mutations in the
RAB23 gene [24]. The Gorlin syndrome (nevoid basal cell
carcinoma syndrome) also manifests macrocephaly, and
occasionally manifests hypertelorism and polydactyly.
Gorlin syndrome is caused by mutations in PTCH1,
another gene in the GLI-SHH pathway [25].
Recurrence risks
In multiplex families affected with GCPS, the recurrence
risk for affected persons is 50%. The penetrance of GCPS
is high, but is not 100% [7]. Therefore, unaffected persons
from multiplex families have a risk for affected children
that is probably less than 1% per conception. Apparently
unaffected parents of simplex (apparently de novo) affect-
eds should be examined carefully for subtle signs of the
disorder and molecular testing is indicated. If they mani-
fest no signs of the disorder and do not carry the mutation
seen in the affected child, they should be advised of a
small recurrence risk, again probably less than 1% per
conception. Gonadal mosaicism for GCPS has not been
reported, but there is no reason to assume that this is not
possible.
For multiplex families, the severity of the phenotype in
that family is the best guide to the likely severity of future
affected offspring in that family. That is because the intra-
familial variability is less than the interfamilial variability.
It warrants re-emphasizing that the risk of cognitive
impairment in GCPS caused by point mutations or dele-
tions less than 1 Mb may not be significantly elevated over
background rates. It is true that there are a modest excess
of cognitively impaired children with GCPS among
research cohorts, but again, ascertainment bias for
increased enrollment of children with developmental dis-
abilities may account for much or all of this elevation.
Molecular diagnostics play a key role in the evaluation of
simplex cases with manifestations compatible with GCPS-
CGS or acrocallosal syndrome. Because the latter is inher-
ited as an autosomal recessive trait, distinguishing these
two diagnoses dramatically changes the recurrence risk
(<1% vs. 25%) for the parents of the affected child.
Although the gene for acrocallosal syndrome has not been
determined, testing for a large deletion of the GLI3 locus
can be critical to make this distinction.
As in all rare dominantly inherited disorders caused by
loss of function mutations, the mutational spectrum of
GCPS is broad and in some families it may be difficult to
determine with certainty that the detected sequence vari-
ant is causative. These variants should be interpreted with
caution.
Antenatal diagnosis
Antenatal molecular diagnosis is technically straightfor-
ward to perform (via amniocentesis or chorionic villusPage 4 of 6
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tive point mutation has previously been determined. As
noted in the previous section, some unique mutations
detected in patients with GCPS can be difficult to interpret
and in such cases, prenatal molecular diagnosis should be
approached with caution. Antenatal diagnosis may also
be undertaken for chromosomal aberrations that cause
GCPS (translocations, large deletions, etc.) and the con-
siderations for performing these tests antenatally are no
different than those associated with other phenotypes.
Antenatal ultrasound may also be used to assess polydac-
tyly. The ultrasound finding of macrocephaly is probably
not sufficiently specific to be used for antenatal diagnosis
of GCPS. High-resolution ultrasound can detect fetuses
with polydactyly.
Management including treatment
There are few associated medical complications of GCPS.
Generally, the patients are healthy and have a normal
lifespan. Surgical treatment of polysyndactyly should be
considered, and in many cases leads to excellent outcome.
As noted above, some patients with GCPS can have cogni-
tive delays, although in GCPS these are typically mild.
Proper developmental assessment and early intervention
should be offered to any patient manifesting developmen-
tal delay. The nature of the intervention that is appropri-
ate for patients with GCPS cannot be specified solely on
the basis of the diagnosis. Instead, patients should be
assessed individually and the appropriate interventions
implemented.
Prognosis
The prognosis of typical GCPS is good with a low or back-
ground rate of cognitive impairment, which is typically
the most worrisome manifestation of the disorder among
affected families. Polydactyly is straightforward to treat in
many instances, although it can be complex when the
patient has severe cutaneous syndactyly. Postaxial poly-
dactyly is easier to repair than is preaxial polydactyly, and
the latter should be performed only by experienced sur-
geons. Surgical repair of the hands is important for both
functional and esthetic reasons. Our group is aware of a
family where postaxial polydactyly type A was not
repaired, as the digit was normally formed and fully func-
tional. Surgical repair of the feet is optional in many cases
as esthetic considerations are generally less pressing (com-
pared to the hands) and the functional consequences of
iatrogenic biomechanical problems can be severe.
Unresolved questions
The complete spectrum of phenotypes attributable to
GLI3 mutations has not been fully delineated, again
because of ascertainment bias. This author suspects that
there are a number of other candidate phenotypes, such as
oral-facial-digital syndromes, that may be caused by GLI3
mutations. As well, GLI3 mutations may cause non-syn-
dromic polydactyly, although this diagnosis can be diffi-
cult to make with confidence [19]. As noted above, not all
patients with GCPS have GLI3 mutations and molecular
diagnostic tools to assess these patients would be clini-
cally useful.
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